Clinically, while kinase inhibitors like imatinib have shown limited success in inhibiting CSF-1R function, monoclonal antibodies (mAb) such as RG7155 have demonstrated significant efficacy in reducing TAMs and stabilizing disease in various cancers, highlighting CSF-1R as a promising therapeutic target [80]. This evidence concerns the gene CSF1R and cancer.